Clinical and laboratory features of myelofibrosis and limitations of current therapies

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 9, 2011, Pages 1-3

  Gregory, Stephanie A ^a   Mesa, Ruben A ^b   Hoffman, Ronald ^c   Shammo, Jamile M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HYDROXYUREA; INCB 18242; RUXOLITINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; GENE; GENE MUTATION; HUMAN; JANUS KINASE TYPE 2 GENE; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; POLYCYTHEMIA VERA; PROGNOSIS; SURVIVAL TIME; THROMBOCYTHEMIA;

HUMANS; PRIMARY MYELOFIBROSIS;

EID: 80054687489     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)